Emergent Biosolutions Inc (EBS)
Emergent BioSolutions Inc. is a healthcare company focused on preparedness and response solutions for public health threats that are accidental, deliberate, or naturally occurring. The company operates in the United States, Canada, and international markets, and reports results through Commercial Products, MCM Products, and All Other Revenues segments. Its portfolio includes vaccines and therapeutics for threats such as smallpox, mpox, anthrax, botulism, Ebola, and opioid overdose, including ACAM2000, BioThrax, CYFENDUS, Ebanga, TEMBEXA, NARCAN, and KLOXXADO. Emergent also provides contract development and manufacturing services, including drug substance and product manufacturing, packaging, and related development and transfer services. Incorporated in 1998, the company is headquartered in Gaithersburg, Maryland.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-EBS
|
$7.20
|
5.9% Upside
|
Fair
|
$11
|
61.8% Upside
|
Bargain
|
Great
|
0.0%
|
November 11, 2026
|
1.1x
|
0.5x
|
348.7 M
|
808.4 M
|
62.0%
|
95.3%
|
1.9
|
-48.6%
|
